

## Formaldehyde stress

HE RongQiao<sup>1\*</sup>, LU Jing<sup>1,2</sup> & MIAO JunYe<sup>1,2</sup>

<sup>1</sup>State Key Laboratory of Brain and Cognitive Sciences, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China;

<sup>2</sup>Graduate University of Chinese Academy of Sciences, Beijing 100049, China

Received November 1, 2010; accepted November 19, 2010

Formaldehyde, one of the most toxic organic compounds, is produced and processed in human cells. The level of human endogenous formaldehyde is maintained at a low concentration (0.01–0.08 mmol L<sup>-1</sup> in blood) under physiological conditions, but the concentration increases during ageing (over 65 years old). Clinical trials have shown that urine formaldehyde concentrations are significantly different between elderly Alzheimer's patients ( $n=91$ ) and normal elderly volunteers ( $n=38$ ) ( $P<0.001$ ). Abnormally high levels of intrinsic formaldehyde lead to dysfunction in cognition such as learning decline and memory loss. Excess extracellular and intracellular formaldehyde could induce metabolic response and abnormal modifications of cellular proteins such as hydroxymethylation and hyperphosphorylation, protein misfolding, nuclear translocation and even cell death. This cellular response called formaldehyde stress is dependent upon the concentration of formaldehyde. Chronic impairments of the brain resulted from formaldehyde stress could be one of the mechanisms involved in the process of senile dementia during ageing.

**formaldehyde, Alzheimer's disease, senile dementia, stress, cognition, impairment, hyperphosphorylation**

**Citation:** He R Q, Lu J, Miao J Y. Formaldehyde stress. *Sci China Life Sci*, 2010, 53: 1399–1404, doi: 10.1007/s11427-010-4112-3

Familial Alzheimer's disease is a very rare autosomal dominant disease with early onset. In contrast with familial disease, sporadic Alzheimer's disease is very common [1]. Even though senile dementia has been widely studied [2–6], the exact cause of the sporadic form of the disease remains unknown. Epidemiological research has shown that exogenous formaldehyde exposure leads to human cognitive decline, and is associated with neurofilament and cytoskeleton disruptions and axonal demyelination [7–9]. Though stress induced by exogenous formaldehyde on *Methylobacterium* [10], rats [11] and humans [12] has been reported, the cellular mechanism needs to be investigated. Here, we show the role of excess endogenous formaldehyde as a putative risk factor that is related to sporadic senile dementia. Formaldehyde stress occurs in a cell when either extracellular or intracellular formaldehyde is elevated abnormally.

### 1 Formaldehyde commonly exists in exogenous and endogenous human environments

Formaldehyde may have been produced by photochemical reactions in the Earth's primitive atmosphere at a time when it consisted mainly of molecular nitrogen, water vapor, carbon dioxide, and trace amounts of molecular hydrogen and carbon monoxide [13]. According to the *Toxicological Review of Formaldehyde Inhalation Assessment* by the Environmental Protection Agency USA (June 18, 2010), formaldehyde is present in a wide variety of products including some plywood adhesives, abrasive materials, insulation, insecticides and embalming fluids. The major sources of anthropogenic emissions of formaldehyde are motor vehicle exhaust, power plants, petroleum refineries, coking operations, incinerating, wood burning, and tobacco smoke. Formaldehyde is used in industry to manufacture building materials and numerous household products and consumer products. To a certain extent, humans live in an environ-

\*Corresponding author (email: rongqiaohe@gmail.com)

**Table 1** Generation and degradation of intrinsic formaldehyde

Formaldehyde generation	Localization	Formaldehyde degradation	Localization
Lysine specific demethylase 1 (LSD1)	Nucleus [14]	Alcohol dehydrogenase I (ADH1)	Cytoplasm [23]
Serine hydroxymethyl transferase (SHMT)	Cytoplasm mitochondria [15]	Alcohol dehydrogenase III (ADH3 or ADH5)	Cytoplasm nucleus [24]
Semicarbazide-sensitive amine oxidase (SSAO)	Cytoplasm, membrane [16]	Formaldehyde dehydrogenase (FDH/ADHIII)	Cytoplasm nucleus [23]
Dimethylglycine dehydrogenase (DMGDH)	Mitochondria [17,18]	Aldehyde dehydrogenase 2 (ALDH2)	Mitochondria [23]
AO (alcohol oxidase)	Peroxisome [19]		
Vanillate-O-demethylase (V-O-DMT)	Endoplasmic reticulum [20]		
Lipid peroxidation (LPO)	Membrane lipid [21]		
P450 (CYP2E1)	Mitochondria [22]		


ment containing extrinsic formaldehyde.

As described by Pinto *et al.* [13], reactions of formaldehyde in the primordial aquatic environment would have had implications for the abiotic synthesis of complex organic molecules and the origin of life, i.e., formaldehyde has been involved in living processes from the beginning of life. Pathways which have been found to produce formaldehyde in the human body are shown in Table 1. Organelles within living cells, including the nucleus, cytoplasm, mitochondria, endoplasmic reticulum and membranes, synthesize and release formaldehyde continuously. Formaldehyde metabolism is catalyzed by several enzymes and participates in pathways such as the methylation of DNA [20,25]. Formaldehyde is also produced from the reaction of malondialdehyde with protein [26]. These reports show that humans also live in an environment containing intrinsic formaldehyde.


## 2 Excess formaldehyde leads to hyper-modification and misfolding of proteins

The half lethal dose ( $LD_{50}$ ) of formaldehyde in SH-SY5Y cells is 0.1–0.2 mmol  $L^{-1}$  [26]. As described previously (Figure 1), formaldehyde causes Tau protein misfolding resulting in amorphous deposits *in vitro*, which can bind to thioflavin T (ThT) and Congo Red [27,28]. One of the major products of the reaction between formaldehyde and the  $\alpha/\epsilon$ -amino groups of amino acids is hydroxymethylation. These ThT-positive Tau aggregates induce cellular apoptosis of SH-SY5Y cells and rat hippocampal cells (Figure 2A–D) [29]. Pore-like polymers can be observed after Tau protein is incubated overnight with formaldehyde at 0.5% or higher concentrations (Figure 1E–G) [30], a concentration that is much higher than the  $LD_{50}$  for formaldehyde in humans [31]. Further investigation is thus needed to establish whether abnormal elevation of formaldehyde results in pore-like protein aggregations *in vivo*.

Using antibodies (Figure 2), we observed that cellular Tau protein [32] was phosphorylated (Thr-181 and Ser-396) when N2a and SH-Y5Y cells were incubated with formaldehyde (around 0.1 mmol  $L^{-1}$ ). Furthermore, hyperphosphorylated Tau protein was ThS-positive in the vesicles of



**Figure 1** Tau protein in the presence of formaldehyde. Amorphous deposits are observed when Tau protein is incubated with 0.1% formaldehyde for 12 h. A, Atomic force microscopy. B, Electron microscopy. Pore-like aggregates are observed in the presence of 0.5% (or higher concentrations) formaldehyde (E–G). Native Tau (D) and samples incubated without formaldehyde (C) were employed as controls.




**Figure 2** Cells in the presence of formaldehyde and hydroxymethylated Tau. The same SH-SY5Y cells were imaged after incubation with Tau deposits (2  $\mu\text{mol } L^{-1}$ ) for 0, 24, 48 or 72 h (A–D). Cells were visualized by inverted contrast microscopy. The neurites became atrophic, and neurons became round in the presence of formaldehyde. Formaldehyde at low concentrations induces phosphorylation, misfolding and aggregation of Tau protein (E–L). Aggregates were ThS-positive. Tau protein was hyperphosphorylated (T231) in the hippocampus of methanol-fed mice (M).

these cells, suggesting misfolding of the modified protein. To confirm that hyperphosphorylation of Tau protein occurs in the presence of formaldehyde, we injected mice intraperitoneally with formaldehyde or fed them with methanol. Hyperphosphorylation of Tau was detected in the hippocampus with a monoclonal antibody (Thr-231). These results suggest that administration of formaldehyde promotes hyperphosphorylation of Tau in neural cells and in the mouse brain.

### 3 Formaldehyde stress

Abnormal elevation of extrinsic and intrinsic formaldehyde promotes hyperphosphorylation of Tau protein and its aggregation [27,28] and increases amyloid- $\beta$  deposits [33], accompanied with cellular dysfunction and even apoptosis [28]. Illumina Solexa DNA sequencing exhibited that more than 100 genes were up- or down-regulated in the metabolic pathway in SH-SY5Y cells treated by formaldehyde. Simultaneously, cell shrinkage and rounding can be observed. Thus, formaldehyde stress is properly described as metabolic response and hyper-modifications of protein such as hyperphosphorylation induced by excess concentrations of formaldehyde, followed by protein misfolding and aggregation (Figure 3), accompanied with cell shrinkage and rounding.

Excess formaldehyde can also lead to endoplasmic reticulum stress, leaving proteins unfolded or misfolded in the cytoplasm [27]. The unfolded protein response is activated in response to an accumulation of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum [34]. While formaldehyde stress and endoplasmic reticulum stress can both activate the unfolded protein response, endoplasmic reticulum stress is somewhat different from for-




**Figure 3** A putative scheme for formaldehyde stress. Formaldehyde stress is best described as hyper-modifications of protein such as hydroxymethylation and hyperphosphorylation in the presence of excess concentrations of formaldehyde, followed by protein unfolding, misfolding and aggregation.

maldehyde stress in that hyper-modifications of proteins occur in formaldehyde stress and some modified proteins are transferred into the nucleus.

### 4 Formaldehyde-induced chronic impairment and sporadic senile dementia

According to our clinical studies, the concentration of endogenous formaldehyde tends toward homeostasis (around  $0.083 \text{ mmol L}^{-1}$  in urine) under physiological conditions, but increases with ageing (Figure 4). The urine formaldehyde concentrations of elderly Alzheimer's patients ( $n=91$ ) and normal elderly volunteers ( $n=38$ ) are significantly different ( $P<0.001$ ) [35,36]. Blood formaldehyde ( $0.01\text{--}0.08 \text{ mmol L}^{-1}$ ) should be freshly assayed because formaldehyde is very active to react with serum protein. The other lab using HPLC/spectrophotometric procedures has found that the concentration of endogenous formaldehyde in human plasma is  $0.017\text{--}0.143 \text{ mmol L}^{-1}$  [37]. Measurement of saliva formaldehyde is uneasy to correctly perform either on clinic because of elderly people having a low secretion of saliva. Concentrations of formaldehyde in the hippocampus of Alzheimer's patients are significantly higher than those of controls. Formaldehyde concentration in the brain of SAMP8 mouse with cognitive disorders is markedly higher than that in the brain of SAMR1 mouse as the control. Similarly six-month-old APP-transgenic mouse and three-month-old APP/PS1-transgenic mouse have higher formaldehyde concentrations than controls. Abnormally high concentrations of formaldehyde further lead to dysfunction of the hippocampus and cognitive impairment [35]. Chronic impairments of gray matter and white matter in the brain of



**Figure 4** The homeostasis of formaldehyde metabolism *in vivo*. The concentration of endogenous formaldehyde tends to reach equilibrium under normal physiological conditions via synthesis and degradation. We hypothesized that chronic impairment of the central nervous system caused by abnormal elevation of endogenous formaldehyde may be one of the important risk factors for sporadic Alzheimer's disease during ageing.

Alzheimer's patients may result from formaldehyde stress. Illumina Solexa DNA sequencing suggests that some genes related to Alzheimer's disease are strikingly up-regulated in SH-SY5Y cells in the presence of formaldehyde at LD<sub>50</sub>. That is, abnormal elevation of endogenous formaldehyde may be one of the risk factors which contribute to some cases of sporadic senile dementia.

## 5 Formaldehyde stress, clinical trials, and drug design

According to our investigations of senior citizens in Beijing, about 20%–40% of senile dementia patients have abnormally elevated urine formaldehyde levels. This suggests that elevated formaldehyde plays a role in senile dementia. The concentration of urine formaldehyde was positively related to cognitive impairments in some patients. Thus, measurement of urine formaldehyde concentration could be used alongside a cognitive questionnaire as a biomarker to support clinical diagnosis.

Further investigations should be carried out using animal models (mice, rats and monkeys) of formaldehyde-induced chronic impairments of the central nervous system. For example, animals could be administered with formaldehyde at certain doses over a relatively long period (1–2 years), and then changes in their brains and cognitive functions could be assessed. The structure and function of formaldehyde metabolic enzymes from Alzheimer's patients and animal models should also be studied. Drugs for decreasing endogenous formaldehyde levels could be designed and evaluated using animal models.

## 6 Other studies on formaldehyde and Alzheimer's disease

Our previous work has shown that formaldehyde at low concentrations induces Tau protein aggregation in the cytoplasm [27]. Amyloid- $\beta$  deposits increase in the presence of formaldehyde [33]. Furthermore, disorders in cognitive behaviors occur when animals are exposed to formaldehyde [7,8]. We need to emphasize that not all cases of senile dementia are correlated with an elevation in endogenous formaldehyde or with the dysfunction of formaldehyde metabolism, since the causes of senile dementia are extremely complex. International colleagues have done much work and made great progress in research on Alzheimer's disease [38–42]. At the same time, Chinese researchers have also made important advances in studies on neurodegeneration, including studies on protein misfolding and aggregation [43], hippocampus structure and function [44],  $\beta$ -secretase [45,46], amyloid-beta [47–49], hyperphosphorylation [50–53], and dephosphorylation [54], glycation [55–58], related genes and

special RNA [59–61], reactive oxygen species [62], white matter denaturation [63], ubiquitin and proteasome [64], apoptosis [65], plasticity and memory [59,66], chronic inflammation [67], prevention of brain and cognitive function [68,69] as well as clinical studies [70,71]. Although formaldehyde has been shown to play a role in the senile dementia process, much work is still required, especially to elucidate the cellular and molecular events involved in formaldehyde stress.

*This work was supported by the National Basic Research Program of China (Grant Nos. 2010CB912303 and 2006CB500703), the National Natural Science Foundation of China (Grant No. 30970695) and the Knowledge Innovation Project of Chinese Academy of Sciences (Grant Nos. KSCX2-YW-R-256 and CAS-KSCX2-YW-R-119). We thank Ms. Qiang Min for her editing of Table 1 and the references.*

- 1 Blennow K, de Leon M J, Zetterberg H, et al. Alzheimer's disease. *Lancet*, 2006, 368: 387–403
- 2 Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends Pharmacol Sci*, 1991, 12: 383–388
- 3 Flament S, Delacourte A, Mann D M. Phosphorylation of Tau proteins: A major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome. *Brain Res*, 1990, 516: 15–19
- 4 Bignall J. APOE gene dose in Alzheimer's disease. *Lancet*, 1993, 342: 426
- 5 Anwar R, Moynihan T P, Ardley H, et al. Molecular analysis of the presenilin 1 (S182) gene in "sporadic" cases of Alzheimer's disease: Identification and characterisation of unusual splice variants. *J Neurochem*, 1996, 66: 1774–1777
- 6 Bertoni-Freddari C, Fattoretti P, Paoloni R, et al. Impaired dynamic morphology of cerebellar mitochondria in physiological aging and Alzheimer's disease. *Ann NY Acad Sci*, 1997, 826: 479–482
- 7 Kilburn K H, Warshaw R, Thornton J C. Formaldehyde impairs memory, equilibrium, and dexterity in histology technicians: Effects which persist for days after exposure. *Arch Environ Health*, 1987, 42: 117–120
- 8 Kilburn K H. Neurobehavioral impairment and seizures from formaldehyde. *Arch Environ Health*, 1994, 49: 37–44
- 9 Perna R B, Bordini E J, Deinzer-Lifrak M. A case of claimed persistent neuropsychological sequelae of chronic formaldehyde exposure: Clinical, psychometric, and functional findings. *Arch Clin Neuropsychol*, 2001, 16: 33–44
- 10 Miller J A. Formaldehyde stress response in *Methylobacterium extorquens* AM1. Ph.D. Thesis. Washington, USA: University of Washington, 2009. 10
- 11 Joseph M M, Norman W. The rapid activation of tyrosine hydroxylase by the subcutaneous injection of formaldehyde. *Life Sci*, 1981, 29: 2025–2029
- 12 Bottiglionie, Sturani P L. Formaldehyde stress and experimental tuberculous. II. Modifications of ground substance of the connective tissue in the skin, in the specific granuloma and in the kidneys. *Arch Patol Clin Med*, 1955, 32: 210–219
- 13 Pinto J P, Gladstone G R, Yung Y L. Photochemical production of formaldehyde in earth's primitive atmosphere. *Science*, 1980, 210: 183–185
- 14 Andres N, Lizcano J M, Rodriguez M J, et al. Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. *J Histochem Cytochem*, 2001, 49: 209–217
- 15 Bell-Parikh L C, Guengerich F P. Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. *J Biol Chem*, 1999, 274: 23833–23840

- 16 Binkova B, Sram R J. Lipid-peroxidation in biological-membranes. *Chemicke Listy*, 1989, 83: 1065–1084
- 17 Iborra F J, Renau-Piqueras J, Portoles M, et al. Immunocytochemical and biochemical demonstration of formaldehyde dehydrogenase (class III alcohol dehydrogenase) in the nucleus. *J Histochem Cytochem*, 1992, 40: 1865–1878
- 18 Jelski W, Chrostek L, Szmitkowski M, et al. Activity of class I, II, III, and IV alcohol dehydrogenase isoenzymes in human gastric mucosa. *Dig Dis Sci*, 2002, 47: 1554–1557
- 19 Jelski W, Sani T A, Szmitkowski M. Class III alcohol dehydrogenase and its role in the human body. *Postepy Hig Med Dosw (Online)*, 2006, 60: 406–409
- 20 Lambert C E, Shank R C. Role of formaldehyde hydrazone and catalase in hydrazine-induced methylation of DNA guanine. *Carcinogenesis*, 1988, 9: 65–70
- 21 Binzak B A, Wevers R A, Moolenaar S H, et al. Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency. *Am J Hum Genet*, 2001, 68: 839–847
- 22 Hibi M, Sonoki T, Mori H. Functional coupling between vanillate-O-demethylase and formaldehyde detoxification pathway. *Fems Microbiol Lett*, 2005, 253: 237–242
- 23 Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell*, 2004, 119: 941–953
- 24 Stover P J, Chen L H, Suh J R, et al. Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene. *J Biol Chem*, 1997, 272: 1842–1848
- 25 Teng S, Beard K, Pourahmad J, et al. The formaldehyde metabolic detoxification enzyme systems and molecular cytotoxic mechanism in isolated rat hepatocytes. *Chem Biol Interact*, 2001, 130–132: 285–296
- 26 Li F X, Lu J, Xu Y J, et al. Formaldehyde-mediated chronic damage may be related to sporadic neurodegeneration. *Prog Biochem Biophys*, 2008, 35: 393–400
- 27 Nie C L, Wei Y, Chen X Y, et al. Formaldehyde at low concentration induces protein Tau into globular amyloid-like aggregates *in vitro* and *in vivo*. *PLoS ONE*, 2007, 2: e629
- 28 Nie C L, Zhang W, Zhang D, et al. Changes in conformation of human neuronal tau during denaturation in formaldehyde solution. *Protein Pept Lett*, 2005, 12: 75–78
- 29 Nie C L, Wang X S, Liu Y, et al. Amyloid-like aggregates of neuronal tau induced by formaldehyde promote apoptosis of neuronal cells. *BMC Neurosci*, 2007, 8: 9
- 30 Naqvi S H, Wang W S, Miao J Y, et al. Pore-like aggregates of Tau protein induced by formaldehyde (in press). *Prog Biochem Biophys*, 2010, 37: 1195–1203
- 31 Klaassen C D. Casarett and Doull's Toxicology: The Basic Science of Poisons. 6th ed. Beijing: People's Medical Publishing House, 2002. 894–895
- 32 Sheng Z L, Qu M H, He H J, et al. Localization of Tau protein in SH-SY5Y, HeLa and HEK293 cells. *Prog Biochem Biophys*, 2008, 35: 1364–1370
- 33 Chen K, Maley J, Yu P H. Potential implications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. *J Neurochem*, 2006, 99: 1413–1424
- 34 Mori K. Cellular response to endoplasmic reticulum stress mediated by unfolded protein response pathway. *Tanpakushitsu Kakusan Koso*, 1999, 44: 2442–2448
- 35 Tong Z Q, Zhang J L, Luo W H, et al. Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. *Neurobiol Aging*, 2011, 32: 31–34
- 36 Wang W S, HAO Z H, Zhang L, et al. Research on urine formaldehyde concentration in Alzheimer's disease elderly and normal elderly. *Chin J Geriatr Heart Brain Vessel Dis*, 2010, 12: 721–722
- 37 Erkrath K D, Adebahr G, Kloppel A. Lethal intoxication by formalin during dialysis (author's transl). *Z Rechtsmed*, 1981, 87: 233–236
- 38 Gong Y, Chang L, Viola K L, et al. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc Natl Acad Sci USA*, 2003, 100: 10417–10422
- 39 Roberson E D, Scearce-Levie K, Palop J J, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science*, 2007, 316: 750–754
- 40 Urošević N, Martins R N. Infection and Alzheimer's disease: The APOE epsilon4 connection and lipid metabolism. *J Alzheimers Dis*, 2008, 13: 421–435
- 41 Muller M, Cheung K H, Foskett J K. Enhanced ROS generation mediated by Alzheimer's disease presenilin regulation of InsP3R Ca<sup>2+</sup> signaling. *Antioxid Redox Signal*, 2010, doi:10.1089/ars.2010.3421
- 42 Du H, Guo L, Yan S, et al. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. *Proc Natl Acad Sci USA*, 2010, 107: 18670–18675
- 43 Feng Y, Zhang M, Hu M, et al. Disassembly intermediates of RbsD protein remain oligomeric despite the loss of an intact secondary structure. *Sci China Ser C-Life Sci*, 2009, 52: 997–1002
- 44 Jiao G H, Liu C W, Zhang T, et al. Lithium carbonate modulation of delayed rectifier potassium channel involves protein kinase C/mitogen-activated protein kinase signaling in hippocampus of rats. *Prog Biochem Biophys*, 2008, 35: 814–821
- 45 Lu J L, Chu J, Yang J, et al. Detection of beta-secretase dimerization in living cells using acceptor photobleaching FRET. *Prog Biochem Biophys*, 2008, 35: 268–273
- 46 Zhang D L, Liang L Y, Ji T T, et al. Variation of monoamine neurotransmitter in forebrain of presenilin-1/presenilin-2 double knockout mice. *Prog Biochem Biophys*, 2009, 36: 1436–1441
- 47 Liu L, Zhang L, Mao X B, et al. Chaperon-mediated single molecular approach toward modulating A beta peptide aggregation. *Nano Lett*, 2009, 9: 4066–4072
- 48 Zhang Y W, Wangt R S, Liu Q, et al. Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. *Proc Natl Acad Sci USA*, 2007, 104: 10613–10618
- 49 Wu W H, Lei P, Liu Q, et al. Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. *J Biol Chem*, 2008, 283: 31657–31664
- 50 Shi Y G. Assembly and structure of protein phosphatase 2A. *Sci China Ser C-Life Sci*, 2009, 52: 135–146
- 51 Yang X, Yang Y, Luo Y, et al. Hyperphosphorylation and accumulation of neurofilament proteins in transgenic mice with Alzheimer presenilin 1 mutation. *Cell Mol Neurobiol*, 2009, 29: 497–501
- 52 Qian W, Shi J, Yin X, et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. *J Alzheimers Dis*, 2010, 19: 1221–1229
- 53 Luo J, Ma J, Yu D Y, et al. Infusion of FK506, a specific inhibitor of calcineurin, induces potent tau hyperphosphorylation in mouse brain. *Brain Res Bull*, 2008, 76: 464–468
- 54 Yang J Y, Gu J L, Shi J H, et al. The inhibitory effect of OGT gene expression on the level of tau phosphorylation. *Prog Biochem Biophys*, 2009, 36: 346–352
- 55 Sheng Z L, Liu Y Y, Chen L, et al. Nonenzymatic glycation of alpha-synuclein and changes in its conformation. *Prog Biochem Biophys*, 2008, 35: 1202–1208
- 56 Wei Y, Chen L, Chen J, et al. Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. *Bmc Cell Biol*, 2009, 10: 10
- 57 Chen L, Wei Y, Wang X Q, et al. d-Ribosylated Tau forms globular aggregates with high cytotoxicity. *Cell Mol Life Sci*, 2009, 66: 2559–2571
- 58 Chen L, Wei Y, Wang X Q, et al. Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. *PLoS ONE*, 2010, 5: e9052
- 59 He R, Wang E D. The important role of three auxiliary factors of mammalian aminoacyl-tRNA synthetase complex in the cellular signaling network. *Prog Biochem Biophys*, 2009, 36: 398–402
- 60 Wang Y, Jia J. Association between promoter polymorphisms in anterior pharynx-defective-1a and sporadic Alzheimer's disease in the

- North Chinese Han population. *Neurosci Lett*, 2009, 455: 101–104
- 61 Yang M, Cai F, Pan Q, *et al.* Transcriptional regulation of the Alzheimer's disease-related gene Nicastrin. *Prog Biochem Biophys*, 2009, 36: 994–1002
- 62 Zhao B L. Protective effects of green tea polyphenols against Parkinson's disease. *Prog Biochem Biophys*, 2008, 35: 735–743
- 63 Tian L J, Du Y R, Xiao Y, *et al.* Mediating roles of the vanilloid receptor TRPV1 in activation of rat primary afferent nociceptive neurons by formaldehyde. *Sheng Li Xue Bao*, 2009, 61: 404–416
- 64 Li X A, Zhang Y J, Chang M, *et al.* Dysfunction of proteasome and formation of Lewy body in sporadic Parkinson's disease. *Prog Biochem Biophys*, 2008, 35: 502–511
- 65 Jiang Q, Lin L, Wang T H. A new model for apoptosis research: Yeast. *Prog Biochem Biophys*, 2008, 35: 361–367
- 66 Chen Y. Neuronal synaptic plasticity, learning and memory. *Prog Biochem Biophys*, 2008, 35: 610–619
- 67 Sun Y N, Luo J Y, Rao Z R, *et al.* GFAP and Fos immunoreactivity in lumbo-sacral spinal cord and medulla oblongata after chronic colonic inflammation in rats. *World J Gastroenterol*, 2005, 11: 4827–4832
- 68 Hu J, Li G, Wang H, *et al.* Prevention of pathological change and cognitive degeneration of Tg2576 mice by inoculating Aβ(1-15) vaccine. *Sci China Ser C-Life Sci*, 2008, 51: 743–750
- 69 Yu C, Li G, Zhou L N, *et al.* Effect of deep brain stimulation on neural activity of subthalamic nucleus in rats. *Prog Biochem Biophys*, 2009, 36: 1049–1055
- 70 Bai F, Liao W, Watson D R, *et al.* Mapping the altered patterns of cerebellar resting-state function in longitudinal amnesic mild cognitive impairment patients. *J Alzheimers Dis*, 2010, doi: 10.3233/JAD-2010-101533
- 71 Yu G, Jia J. Is there an association of regulatory region polymorphism in the alpha-1-antichymotrypsin gene with sporadic Alzheimer's disease in the northern Han-Chinese population? *J Clin Neurosci*, 2010, 17: 766–769